Diaceutics (LON:DXRX) Sets New 1-Year High – Time to Buy?

Shares of Diaceutics PLC (LON:DXRX) hit a new 52-week high on Tuesday. The company traded as high as GBX 199.50 and last traded at GBX 199.50, with a volume of 550495 shares changing hands. The stock had previously closed at GBX 193.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group restated a “buy” rating and set a GBX 215 price objective on shares of Diaceutics in a research report on Tuesday, September 22nd. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of GBX 215.

Diaceutics Stock Performance

The company has a fifty day moving average price of GBX 156.70 and a two-hundred day moving average price of GBX 153.82. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. The company has a market capitalization of £169.30 million, a P/E ratio of -623.44 and a beta of 0.88.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. Equities analysts forecast that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.